Celldex Therapeutics, Inc. (NASDAQ:CLDX) rose 10.8% during mid-day trading on Wednesday . The stock traded as high as $5.84 and last traded at $5.53. Approximately 1,245,907 shares were traded during trading, an increase of 190% from the average daily volume of 429,254 shares. The stock had previously closed at $4.99.
CLDX has been the subject of several research analyst reports. HC Wainwright set a $30.00 price target on Celldex Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 19th. Bank of America raised Celldex Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 15th. Zacks Investment Research upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Monday, January 14th. Finally, ValuEngine upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $30.94.
The firm has a market capitalization of $820.94 million, a P/E ratio of -6.98 and a beta of 4.47.
WARNING: “Celldex Therapeutics (CLDX) Stock Price Up 10.8%” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.com-unik.info/2019/02/13/celldex-therapeutics-cldx-stock-price-up-10-8.html.
About Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.